All In Biotech

Drug Trial Radar · NCT06926868

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Sep 11, 2025

Primary completion

Mar 13, 2028

Study completion May 15, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
SystImmune Inc.
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.

Conditions

  • Breast Neoplasms

Interventions

  • Iza-brenDrug

    Specified dose on specified days

  • Nab-paclitaxelDrug

    Specified dose on specified days

  • PaclitaxelDrug

    Specified dose on specified days

  • CapecitabineDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • GemcitabineDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Approximately 22 months from first participant randomization in Phase 3
  2. Recommended Phase 3 Dose (RP3D) of BMS-986507Time frame: Approximately 13 months from first participant randomization in Phase 2

Locations

296 sites in 28 countries. Site status is shown where the registry gives one.

  • Local Institution - 0303

    Hot Springs, Arkansas · Not yet recruiting

  • Local Institution - 0307

    Cerritos, California · Withdrawn

  • Local Institution - 0308

    Cerritos, California · Withdrawn

  • Local Institution - 0309

    Cerritos, California · Withdrawn

  • Local Institution - 0328

    Cerritos, California · Active not recruiting

  • Local Institution - 0311

    Long Beach, California · Withdrawn

  • Local Institution - 0290

    Los Angeles, California · Completed

  • Local Institution - 0283

    Los Angeles, California · Completed

  • Local Institution - 0353

    Newport Beach, California · Completed

  • Local Institution - 0358

    Stanford, California · Withdrawn

  • Local Institution - 0289

    Aurora, Colorado · Not yet recruiting

  • Local Institution - 0367

    Denver, Colorado · Active not recruiting

  • Local Institution - 0304

    Newark, Delaware · Completed

  • Local Institution - 0296

    Pembroke Pines, Florida · Withdrawn

  • Local Institution - 0294

    Atlanta, Georgia · Completed

  • Local Institution - 0357

    Atlanta, Georgia · Completed

  • Local Institution - 0278

    Chicago, Illinois · Withdrawn

  • Local Institution - 0280

    Chicago, Illinois · Not yet recruiting

  • Local Institution - 0275

    Decatur, Illinois · Completed

  • Local Institution - 0324

    O'Fallon, Illinois · Withdrawn

  • Local Institution - 0286

    Covington, Louisiana · Completed

  • Local Institution - 1035

    Baltimore, Maryland · Withdrawn

  • Local Institution - 0288

    Boston, Massachusetts · Completed

  • Local Institution - 0287

    Boston, Massachusetts · Active not recruiting

  • Local Institution - 0359

    Detroit, Michigan · Completed

  • Local Institution - 0313

    Maple Grove, Minnesota · Completed

  • Local Institution - 0372

    Minneapolis, Minnesota · Withdrawn

  • Local Institution - 0284

    Kansas City, Missouri · Completed

  • Local Institution - 0312

    New York, New York · Withdrawn

  • Local Institution - 0279

    New York, New York · Completed

  • Local Institution - 1037

    Syracuse, New York · Withdrawn

  • Local Institution - 0295

    Westbury, New York · Completed

  • Local Institution - 0285

    White Plains, New York · Completed

  • Local Institution - 0276

    Durham, North Carolina · Completed

  • Local Institution - 0316

    Eugene, Oregon · Completed

  • Local Institution - 0356

    Allentown, Pennsylvania · Active not recruiting

  • Local Institution - 0310

    Philadelphia, Pennsylvania · Completed

  • Local Institution - 0360

    Pittsburgh, Pennsylvania · Withdrawn

  • Local Institution - 0281

    Greenville, South Carolina · Completed

  • Local Institution - 0315

    Austin, Texas · Completed

Showing 40 of 296 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.